Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
American College of Cardiology (ACC) 2018 Annual Scientific Session
March 10 - 12, 2018; Orlando, Florida
March 10 - 12, 2018Orlando, Florida
ACC 2018Barbershop-Based Healthcare Cuts Hypertension in Blacks An outreach program leveraging the community barbershop made impressive inroads combatting hypertension in black men, who have the highest hypertension-related death rate in the United States.
Medscape Medical News, March 12, 2018
ACC 2018ODYSSEY: Alirocumab Cuts CV Events, All-Cause Death Post-ACSFirst evidence of survival benefit with PCSK9 inhibitor alirocumab reignites the call for greater access to these expensive drugs for patients not just with ACS but also with stable atherosclerotic CVD.
Medscape Medical News, March 10, 2018
ACC 2018VEST: No Sudden Death Benefit Early Post-MI From LifeVest But defibrillators work by preventing sudden death, so it's a bit of a head-scratcher that all-cause mortality dropped instead for people who used the wearable defibrillator for 90 days after their MI.
Medscape Medical News, March 10, 2018
Meeting Highlights At A Glance
Top News From ACC 2018: SlideshowHighly anticipated results of the ODYSSEY Outcomes trial of a PCSK9 inhibitor featured prominently at this year's scientific
sessions -- and didn't disappoint.
Evolocumab Added to Statins Cuts CV Events in FOURIER TrialUPDATED // In the heavily anticipated FOURIER outcomes trial, the PCSK9 inhibitor met its primary and key secondary measures.
But is it enough to shut down concerns over costs for the medication class?
SPIRE Trials: Immune Response Thwarts PCSK9 Inhibitor BococizumabIn the trials, which were halted early, a immune response in many patients diminished the drug's potent LDL-lowering effects.
In another analysis, immunogenicity was much less of an issue for alirocumab.
Interviewer: John M. Mandrola MD Interviewee: Gregory G. Schwartz, MD, PhD
Bloggers From The Floor
Pharmacists and Barbers on the Cutting Edge of MedicineDr Mandrola's hands-down favorite study from the 2018 American College of Cardiology meeting showed that a pharmacist-led
intervention in black-owned barbershops cut hypertension in black men.
Ten Quick Thoughts on ODYSSEYDespite a suggested mortality benefit for the PCSK9 inhibitor alirocumab, in high-risk ACS patients, a return to lipid targets
may be the cost-effective lesson from this trial, argues Dr Mandrola.
MOMENTUM-3: The Future of the LVAD Is Here and NowA trial showing better outcomes for HeartMate 3 over HeartMate II sends Dr Walton-Shirley down memory lane to recall the patients
she has referred for implantation of a left ventricular assist device (LVAD).
Another Way to Save a Life: the MANAGE TrialDr Walton-Shirley was impressed by a study on dabigatran for myocardial injury after noncardiac surgery at the American College
of Cardiology Annual Scientific Session.
How Want Became Need With ODYSSEYDr Walton-Shirley would like to prescribe more PCSK9 inhibitors, given positive data from the American College of Cardiology
meeting, but the prior authorization process may break her first